Form 4: Insider Acquires Guided Therapeutics Stock Options

Director Alan Grujic acquired 110,000 stock options for Guided Therapeutics Inc. (GTHP) with an exercise price of $0.29, vesting over several years.

Summary

• Director Alan Grujic acquired 110,000 stock options for Guided Therapeutics Inc. (GTHP).
• The options have an exercise price of $0.29 per share.
• A portion of the options (one-fourth) vested on March 10, 2026.
• The remaining options will vest monthly starting June 10, 2026, and will be fully vested by March 9, 2029, contingent on continued service.
• The filing was made on April 7, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal due to the insider acquisition of options, indicating confidence, but the actual value realization depends on future stock performance.

Positives

• Insider (Director) acquisition of stock options indicates a belief in the company's future prospects.
• The vesting schedule over several years aligns the insider's incentives with long-term company performance.

Risks

• The vesting of options is subject to the reporting person's continued service, implying potential for forfeiture if service is terminated.
• The exercise price of $0.29 suggests that the stock price needs to increase significantly for the options to be profitable.

Future Outlook

The vesting schedule indicates a long-term outlook for the company, with options fully vesting by March 2029, contingent on continued service.

Industry Context

StockSavvy.ai notes that insider acquisition of stock options, particularly by directors, is a common signal of confidence in a company's future performance within the biotechnology and therapeutics sector.

Stakeholder Impact

• Shareholders may view this as a positive signal of insider confidence, potentially influencing investment decisions.
• Employees may be encouraged by the director's commitment, which could indirectly impact morale and retention.

Next Steps

• Continued service by Alan Grujic to ensure full vesting of stock options.
• Monitoring of Guided Therapeutics Inc.'s stock performance relative to the $0.29 exercise price.

Key Dates

Recommendation

This filing represents a standard insider option grant, not a direct purchase of stock with personal funds. While it signals confidence, it does not provide immediate financial results or strategic shifts that would warrant a buy or sell recommendation. A 'hold' is appropriate pending further operational or financial disclosures.

Keywords

Form 4, Insider Trading, Stock Options, Guided Therapeutics, GTHP, Director, Beneficial Ownership, Vesting Schedule